Work Productivity In Patients Research Articles

Back/joint pain, illness perceptions and coping are important predictors of quality of life and work productivity in patients with inflammatory bowel disease: a 12-month longitudinal study.

Back and joint pain are the most common extraintestinal symptoms reported by patients with inflammatory bowel disease (IBD). We assessed the impact of back/joint pain, illness perceptions, and coping on quality of life (QOL) and work productivity in patients with IBD. Our cohort included 155 IBD patients with and 100 without arthropathy. Arthropathy was defined as daily back pain for ≥3 months and/or peripheral joint pain and/or joint swelling over the last year. At baseline and at 12 months, patients completed questionnaires on the extent of back/joint pain, IBD disease activity, illness perceptions, coping, QOL, and work productivity. The impact of back/joint pain, illness perceptions and coping on QOL and work productivity was determined, using linear mixed models. In total, 204 IBD patients (72% Crohn's disease, 40% male, mean age 44 ± 14 years) completed questionnaires at both time points. At both time points, IBD patients with back/joint pain reported a significantly lower QOL and work productivity compared with IBD patients without back/joint pain. Predictors of low QOL were back/joint pain (β = -1.04, 95% confidence interval [CI] -1.40, -0.68), stronger beliefs about the illness consequences (β = -0.39, 95% CI -0.59, -0.18) and emotional impact of IBD (β = -0.47, 95% CI -0.66, -0.28), and the coping strategy 'decreasing activity' (β = -0.26, 95% CI -0.48, -0.03). Predictors of work productivity were back/joint pain (β = 0.22, 95% CI 0.07, 0.37) and illness consequences (β = 0.14, 95% CI 0.06, 0.22). Back/joint pain, illness perceptions, and coping are significant predictors of QOL and work productivity, after controlling for disease activity.

P597. The effects of infliximab treatment failure on health-related quality of life and work productivity in patients with Crohn's disease

P597. The effects of infliximab treatment failure on health-related quality of life and work productivity in patients with Crohn's disease

THU0423 The Impact of Etanercept and Methotrexate Treatment on Work Productivity in Patients with Rheumatoid Arthritis: Results from Phase 2 of the Prize Study

BackgroundRecent studies have demonstrated that biologic agents can improve work productivity in patients with rheumatoid arthritis (RA). However, the long term consequences on work productivity, particularly in step down treatment...

SAT0339 Asas40 and ASDAS Responses Are Associated with Improved Physical Function, Hrqol, and Work Productivity in Patients with Non-Radiographic Axial Spondyloarthritis

BackgroundASAS40 response has been used as a primary endpoint in clinical trials of patients (pts) with axial spondyloarthritis (axSpA), and ASDAS inactive disease is recommended as a treatment target. However,...

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. The Work Limitations Questionnaire (WLQ) is a reliable tool for assessing work productivity in patients with chronic...

220. Ustekinumab Improves Physical Function, General as Well as Arthritis-Related and Skin-Related Quality of Life and Work Productivity of Patients with Active Psoriatic Arthritis Who Were Naïve to Mtx, Despite MTX Therapy or Previously Treated with Anti-TNFα: Results from Psummit I and Psummit II

220. Ustekinumab Improves Physical Function, General as Well as Arthritis-Related and Skin-Related Quality of Life and Work Productivity of Patients with Active Psoriatic Arthritis Who Were Naïve to Mtx, Despite MTX Therapy or Previously Treated with Anti-TNFα: Results from Psummit I and Psummit II

PMS19 - Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials

PMS19 - Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials

AB0860 Impact of treatment with adalimumab on disease activity, work productivity and workday loss in patients with ankylosing spondylitis

BackgroundAnkylosing spondylitis (RS) is chronic inflammatory disease that causes inflammation of the joints between the spinal bones, and the joints between the spine and pelvis. It eventually causes the affected...

OP0105 Effect of Adalimumab on Physical Function, Health-Related Quality of Life, and Work Productivity in Patients with Peripheral Spondyloarthritis: Results from the Ability-2 Clinical Trial

BackgroundSpondyloarthritis is associated with impaired physical function, health-related quality of life (HRQL), and work productivity. Adalimumab (ADA) is associated with improved clinical outcomes in patients with peripheral spondyloarthritis (pSpA).ObjectivesTo evaluate...

AB0415 Impact of different clinical characteristics of rheumatoid arthritis (RA) on work activity of patients

BackgroundWork productivity loss and activity impairment is one of most important RA consequences and leads to considerable financial losses.ObjectivesTo study the effect of RA clinical characteristics on work productivity of...

THU0599 From Bad to Worse? The Impact of Switching Biologic Agents Multiple Times on Work Productivity and Health-Related Quality of Life for Patients with RA.

BackgroundWe are interested in assessing the influence on work productivity in patients with RA who switch their biologic therapy due to lack of efficacy. Investigating the extent of this impact...

SAT0264 Ustekinumab Improves Physical Function, Quality of Life and Work Productivity of Patients With Active Psoriatic Arthritis who were NaÏVe To MTX, Despite MTX Therapy or Previously Treated with Anti-Tnfॅ: Results from Psummit I and Psummit II

ObjectivesTo examine the impact of ustekinumab (UST) treatment on patient reported outcomes in patients with active psoriatic arthritis (PsA) using week 24 data from two Phase 3 clinical studies, PSUMMIT...

PSY16 Effect of the Anti-Tumor Necrosis Factor Adalimumab on Work Productivity in Patients With Chronic Immune-Mediated Inflammatory Diseases: Literature Review

PSY16 Effect of the Anti-Tumor Necrosis Factor Adalimumab on Work Productivity in Patients With Chronic Immune-Mediated Inflammatory Diseases: Literature Review

Impact of Treatment Response on Quality of Life and Work Productivity among Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation: Pooled Results from Phase III Clinical Trials

Purpose: To assess the impact of treatment response on quality of life (QOL) and work productivity for patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC). Methods: Irritable Bowel Syndrome QOL (IBS-QOL) score, EQ-5D score, work productivity, symptom relief, and treatment satisfaction data were collected in phase III randomized placebo-controlled clinical trials of linaclotide, a new treatment for IBS-C and CC. Treatment response for IBS-C was defined as (1) a ≥ 14-point increase in the IBS-QOL overall score from baseline to Week 12 or (2) one of the top two responses (moderately or significantly relieved) in ≥2 out of 3 months on a seven-point Likert scale assessing IBS symptom relief. Response for CC was defined as having (1) one of the top two responses (quite or very satisfied) on a five-point Likert scale assessing treatment satisfaction or (2) having a weekly spontaneous bowel movement (SBM) frequency ≥4 at Week 12. Hours of work missed due to IBS-C or CC were collected using the Work Productivity and Activity Impairment (WPAI) questionnaire. Data from the intent-to-treat populations were pooled for linaclotide and placebo across two trials per condition. EQ-5D and work productivity outcomes were evaluated among responders and non-responders. Results: Approximately 1,500 and 1,200 subjects with available EQ-5D data and 1,100 and 800 with available WPAI data were analyzed from IBS-C and CC trials, respectively. Responders had statistically significantly higher Week 12 EQ-5D scores than non-responders, for all definitions (IBS-QOL: 0.85 vs. 0.81, IBS symptom relief: 0.91 vs. 0.81, CC treatment satisfaction: 0.91 vs. 0.86, CC SBM: 0.90 vs. 0.86; all P<0.05). Responders were statistically significantly less likely to miss ≥1 hour of work during 12 weeks for IBS-C (IBS-QOL: 16.0% vs. 21.7%, IBS symptom relief: 9.6% vs. 20.8%, both P<0.05), but not CC (treatment satisfaction: 7.7% vs. 10.6%, P=0.16; SBM: 8.82% vs. 10.0%, P=0.56). Conclusion: Improvements in disease-specific measures correlate with improvements in health utilities and, to a lesser extent, reduced work absenteeism. Disclosure: Huan Huang and Joseph Menzin: employees of Boston Health Economics, a consultancy whose activities related to this project are funded by Forest Laboratories, Inc., and Ironwood Pharmaceuticals, Inc.; Robyn Carson: employee of Forest Laboratories, Inc. and owns stock and/or stock options in Forest Laboratories, Inc.; Phil Sarocco and Doug Taylor: employees of Ironwood Pharmaceuticals, Inc. and own stock and/or stock options in Ironwood Pharmaceuticals. This research was supported by an industry grant from Forest Laboratories, Inc., and Ironwood Pharmaceuticals, Inc., were involved in the study design; collection, analysis and data interpretation; and decision to submit these data for presentation. Study was sponsored by Forest Laboratories, Inc., and Ironwood Pharmaceuticals, Inc.

Erratum to Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study

Erratum to Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study

PMS48 Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo-Controlled Trial

PMS48 Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo-Controlled Trial

Adalimumab improves health-related quality of life and work productivity in patients with hidradenitis suppurativa: Results from a placebo-controlled phase II trial

Adalimumab improves health-related quality of life and work productivity in patients with hidradenitis suppurativa: Results from a placebo-controlled phase II trial

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities

Psoriasis is associated with a variety of major physical and mental co-morbidities. To assess the incremental burden of co-morbidities on patient-reported outcomes and evaluate the efficacy and safety of adalimumab in psoriasis patients with co-morbidities. Data were obtained from the initial 16-week, double-blind treatment period of REVEAL (Randomized controlled EValuation of adalimumab Every other week dosing in moderate to severe psoriasis triAL), a randomized, multicenter, phase III clinical trial. Patients with moderate to severe psoriasis were randomized in a 2 : 1 ratio to receive adalimumab 80 mg (two 40 mg injections administered subcutaneously) at baseline followed by one 40 mg injection every other week from week 1 to week 15 or placebo. Clinical severity (Psoriasis Area and Severity Index [PASI]) and patient-reported outcomes (Dermatology Life Quality Index [DLQI], Short Form 36 [SF-36] health survey, Work Productivity and Activity Impairment [WPAI] questionnaire) were assessed during the trial. The effect of selected co-morbidities (i.e. hypertension, psoriatic arthritis, hyperlipidemia, obesity, depression, other forms of arthritis, diabetes mellitus, and other cardiovascular diseases) on patient-reported outcomes was evaluated using multivariate analysis of covariance models. Subgroup analyses were performed by co-morbidity type to statistically compare the clinical efficacy, patient-reported outcome benefits, and safety of adalimumab with placebo in the presence of these conditions. Study co-morbidities were each independently associated with significantly greater impairment on at least one general patient-reported outcome measured at baseline (all p < 0.05), with the exception of hyperlipidemia. During the 16-week study, adalimumab patients demonstrated significantly greater PASI 75 response rates (defined as a reduction of at least 75% in PASI scores from baseline) compared with placebo patients for all co-morbidity subgroups. Adalimumab provided consistent improvements in DLQI, SF-36 Physical Component Summary and Mental Component Summary scores, and WPAI total scores from baseline to week 16 within co-morbidity subgroups. Rates of serious adverse events (AEs), serious infectious AEs, and AEs leading to discontinuation were comparable between adalimumab and placebo for patients with co-morbidities. Co-morbidities were associated with additionally impaired health-related quality of life and work productivity in patients with psoriasis. Adalimumab significantly improved efficacy and patient-reported outcomes and was well tolerated in patients with co-morbidities.

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy

Objective:Joint pain and swelling during gout flares may lead to considerable morbidity and disability, having an impact on patient work productivity and social participation. The objective of this study was to assess how gout flares affect these activities in patients with chronic gout refractory to conventional therapy.Methods:A 1-year prospective observational study was conducted among patients with symptomatic disease in the United States in 2001. Inclusion criteria required patients (1) to be age 18 years or older, (2) to have documented, crystal-proven gout, (3) to have symptomatic gout, and (4) to be intolerant or unresponsive to conventional therapy, reflected by SUA ≥ 6.0 mg/dL. Patients were evaluated every 2 months. At each visit, patients completed a gout diary, which included number of flares experienced, duration and severity of each flare, and whether the flare caused: (1) work loss, (2) missed appointments or social events, or (3) impairment of self-care activities. The Short-Form Health Survey (SF-36) was also completed each visit.Results:Analyses were restricted to those who completed the first 6 months of the study (n = 81). Mean number of flares per patient per year was 8.8. Of the patients who were <65 years, 78% reported at least 1 work day lost due to a gout attack during the year. Mean annual work day loss for those <65 years was 25.1 days. A total of 545 of patients reported at least one flare per year that impaired social activities, with a mean of 17.1 social days lost and 52% reported at least one flare per year that compromised normal self-care activities, with a mean of 16.9 days impairment. Correlations between the diary reports and activity-related questions from the SF-36 were significantly positive.Limitations:The study is limited by small sample size, lack of reference group, and inability to explicitly collect employment information. Age under 65 years was used as a proxy for employment eligibility.Conclusion:Flares in patients with chronic gout refractory to conventional therapy significantly affect patient work productivity and social activities.

Adalimumab Treatment and Work Productivity in Patients with Moderate to Severe Psoriasis: Results from a Prospective Clinical Trial

Objective The effect of adalimumab on work productivity and occupational functioning was evaluated in patients with moderate to severe psoriasis during a prospective 24-week open-label, single-center trial. Methods Thirty-four patients received adalimumab 80 mg subcutaneously at week 0, followed by 40 mg every other week from weeks 1 through 24. Patients were allowed to continue previous topical treatments and phototherapy while enrolled. Occupational functioning was evaluated at monthly intervals throughout the study using the Work Productivity and Activity Impairment Questionnaire—Specific Health Problem. Results There was a statistically significant improvement from baseline to week 24 in the percent of impairment while working (P = 0.0029) and in the percent of overall work impairment (P = 0.0026). The percent of work time missed because of psoriasis decreased, but this change did not reach statistical significance (P = 0.11). Conclusion Adalimumab was efficacious in improving work and activity limitations in patients with moderate to severe psoriasis over a 24-week period.